Advertisement

HIV Vaccine Efficacy Trials: RV144 and Beyond

  • Elizabeth Heger
  • Alexandra Schuetz
  • Sandhya VasanEmail author
Chapter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1075)

Abstract

Despite progress in antiretroviral therapy, pre-exposure prophylaxis, microbicides, and other preventive strategies, a vaccine to prevent HIV-1 infection remains desperately needed. Development of an effective vaccine is challenged by several immunologic features of HIV-1 evidenced by the failure of five of the six HIV-1 candidate vaccine efficacy trials to date. This chapter reviews these efficacy trials with a focus on the Phase 3 RV144 trial in Thailand, the only HIV-1 vaccine efficacy trial to show a moderate protective effect of 31% with respect to placebo administration. Although modest, this protection has allowed for the study of potential immunologic correlates of protection to improve development of future HIV-1 pox-protein and other vaccine strategies. Trials in Thailand and South Africa have built upon the RV144 framework to provide additional immunologic insights which enable current and future efficacy testing of related vaccine candidates.

Keywords

HIV Vaccine Correlates Immunogenicity Efficacy 

References

  1. Akapirat S, Karnasuta C, Madnote S, Savadsuk H, Puangkaew J, Rittiroongrad S, Vasan S, Ngauy V, Robb ML, Excler JL, Pitisuttihum P, Rerks-Ngarm S, Michael N, De Souza M, Kim JH, O’Connell R, Karasavvas N, Group RS (2014a) HIV-specific antibody in rectal secretions following late boosts in RV144 participants (RV305). Paper presented at the HIV research for preventionGoogle Scholar
  2. Akapirat S, Karnasuta C, Nguay V, O’Connell R, Pitisuttihum P, Rerks-Ngarm S, Michael N, De Souza M, Kim JH, Karasavvas N (2014b) Antibody responses in Anogenital secretions of RV305 a late boost vaccination of RV144 volunteers. Paper presented at the Conference on Retroviral and Opportunistic InfectionsGoogle Scholar
  3. Akapirat S, Karnasuta C, Vasan S, Ngauy V, Excler JL, Pitisuttihum P, Rerks-Ngarm S, Michael N, De Souza M, Kim JH, O’Connell R, Karasavvas N (2015) Longevity of HIV-specific IgG Responses in RV305 Anogenital Secretions. Paper presented at the keystone HIV vaccine conferenceGoogle Scholar
  4. Akapirat S, Madnote S, Pitisuttihum P, Nitayaphan S, Chariyalertsak S, Puangkaew J, Rittiroongrad S, Chantakulkij S, Phogat S, Sinangil F, Excler JL, Robb ML, Michael N, Kim JH, Vasan S, O’Connell R, Karasavvas N, Group RS (2016a) Characterization of HIV-1 envelope antibody responses following ALVAC-HIV and AIDSVAX®B/E prime-boost vaccinations with varying late boosts (RV306). Paper presented at the HIV research for preventionGoogle Scholar
  5. Akapirat S, Madnote S, Pitisuttihum P, Nitayaphan S, Chariyalertsak S, Rittiroongrad S, Puangkaew J, Chantakulkij S, Phogat S, Sinangil F, Excler JL, Robb ML, Michael N, Kim JH, Vasan S, O’Connell R, Karasavvas N, Group RS (2016b) Characterization of antibody responses in anogenital secretions of ALVAC-HIV and AIDSVAX®B/E prime-boost vaccinations with varying late boosts (RV306). Paper presented at the HIV research for preventionGoogle Scholar
  6. Akapirat S, Vasan S, Pitisuttihum P, Rerks-Ngarm S, Michael N, Excler JL, Kim JH, O’Connell R, Karasavvas N, Group RS (2016c) Specific IgG subclasses induced in RV305, a late boost vaccination of RV144 subjects. Paper presented at the Conference on Retroviral and Opportunistic InfectionsGoogle Scholar
  7. Alam SM, McAdams M, Boren D, Rak M, Scearce RM, Gao F, Camacho ZT, Gewirth D, Kelsoe G, Chen P, Haynes BF (2007) The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes. J Immunol 178(7):4424–4435. doi:178/7/4424 [pii]Google Scholar
  8. Almond D, Kimura T, Kong X, Swetnam J, Zolla-Pazner S, Cardozo T (2010) Structural conservation predominates over sequence variability in the crown of HIV type 1’s V3 loop. AIDS Res Hum Retrovir 26(6):717–723.  https://doi.org/10.1089/aid.2009.0254 CrossRefPubMedGoogle Scholar
  9. Arthos J, Cicala C, Martinelli E, Macleod K, Van Ryk D, Wei D, Xiao Z, Veenstra TD, Conrad TP, Lempicki RA, McLaughlin S, Pascuccio M, Gopaul R, McNally J, Cruz CC, Censoplano N, Chung E, Reitano KN, Kottilil S, Goode DJ, Fauci AS (2008) HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol 9(3):301–309.  https://doi.org/10.1038/ni1566 CrossRefPubMedGoogle Scholar
  10. Baldwin KM, Ehrenberg PK, Geretz A, Prentice HA, Nitayaphan S, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, O’Connell RJ, Kim JH, Thomas R (2015) HLA class II diversity in HIV-1 uninfected individuals from the placebo arm of the RV144 Thai vaccine efficacy trial. Tissue Antigens 85(2):117–126.  https://doi.org/10.1111/tan.12507 CrossRefPubMedPubMedCentralGoogle Scholar
  11. Barouch DH, O’Brien KL, Simmons NL, King SL, Abbink P, Maxfield LF, Sun YH, La Porte A, Riggs AM, Lynch DM, Clark SL, Backus K, Perry JR, Seaman MS, Carville A, Mansfield KG, Szinger JJ, Fischer W, Muldoon M, Korber B (2010) Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med 16(3):319–323.  https://doi.org/10.1038/nm.2089 CrossRefPubMedPubMedCentralGoogle Scholar
  12. Barouch DH, Stephenson KE, Borducchi EN, Smith K, Stanley K, McNally AG, Liu J, Abbink P, Maxfield LF, Seaman MS, Dugast AS, Alter G, Ferguson M, Li W, Earl PL, Moss B, Giorgi EE, Szinger JJ, Eller LA, Billings EA, Rao M, Tovanabutra S, Sanders-Buell E, Weijtens M, Pau MG, Schuitemaker H, Robb ML, Kim JH, Korber BT, Michael NL (2013) Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell 155(3):531–539.  https://doi.org/10.1016/j.cell.2013.09.061 CrossRefPubMedGoogle Scholar
  13. Barouch DH, Alter G, Broge T, Linde C, Ackerman ME, Brown EP, Borducchi EN, Smith KM, Nkolola JP, Liu J, Shields J, Parenteau L, Whitney JB, Abbink P, Ng’ang’a DM, Seaman MS, Lavine CL, Perry JR, Li W, Colantonio AD, Lewis MG, Chen B, Wenschuh H, Reimer U, Piatak M, Lifson JD, Handley SA, Virgin HW, Koutsoukos M, Lorin C, Voss G, Weijtens M, Pau MG, Schuitemaker H (2015) Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys. Science 349(6245):320–324.  https://doi.org/10.1126/science.aab3886 CrossRefPubMedPubMedCentralGoogle Scholar
  14. Binley JM, Lybarger EA, Crooks ET, Seaman MS, Gray E, Davis KL, Decker JM, Wycuff D, Harris L, Hawkins N, Wood B, Nathe C, Richman D, Tomaras GD, Bibollet-Ruche F, Robinson JE, Morris L, Shaw GM, Montefiori DC, Mascola JR (2008) Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol 82 (23):11651–11668. JVI.01762-08 [pii].  https://doi.org/10.1128/JVI.01762-08 CrossRefGoogle Scholar
  15. Bonsignori M, Montefiori DC, Wu X, Chen X, Hwang KK, Tsao CY, Kozink DM, Parks RJ, Tomaras GD, Crump JA, Kapiga SH, Sam NE, Kwong PD, Kepler TB, Liao HX, Mascola JR, Haynes BF (2012a) Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design. J Virol 86(8):4688–4692.  https://doi.org/10.1128/JVI.07163-11 CrossRefPubMedPubMedCentralGoogle Scholar
  16. Bonsignori M, Pollara J, Moody MA, Alpert MD, Chen X, Hwang KK, Gilbert PB, Huang Y, Gurley TC, Kozink DM, Marshall DJ, Whitesides JF, Tsao CY, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Kim JH, Michael NL, Tomaras GD, Montefiori DC, Lewis GK, DeVico A, Evans DT, Ferrari G, Liao HX, Haynes BF (2012b) Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol 86(21):11521–11532.  https://doi.org/10.1128/JVI.01023-12 CrossRefPubMedPubMedCentralGoogle Scholar
  17. Bonsignori M, Kreider EF, Fera D, Meyerhoff RR, Bradley T, Wiehe K, Alam SM, Aussedat B, Walkowicz WE, Hwang KK, Saunders KO, Zhang R, Gladden MA, Monroe A, Kumar A, Xia SM, Cooper M, Louder MK, McKee K, Bailer RT, Pier BW, Jette CA, Kelsoe G, Williams WB, Morris L, Kappes J, Wagh K, Kamanga G, Cohen MS, Hraber PT, Montefiori DC, Trama A, Liao HX, Kepler TB, Moody MA, Gao F, Danishefsky SJ, Mascola JR, Shaw GM, Hahn BH, Harrison SC, Korber BT, Haynes BF (2017) Staged induction of HIV-1 glycan-dependent broadly neutralizing antibodies. Sci Transl Med 9(381).  https://doi.org/10.1126/scitranslmed.aai7514 CrossRefGoogle Scholar
  18. Bournazos S, Klein F, Pietzsch J, Seaman MS, Nussenzweig MC, Ravetch JV (2014) Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell 158(6):1243–1253.  https://doi.org/10.1016/j.cell.2014.08.023 CrossRefPubMedPubMedCentralGoogle Scholar
  19. Brenchley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, Beilman GJ, Nguyen PL, Khoruts A, Larson M, Haase AT, Douek DC (2004) CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 200(6):749–759.  https://doi.org/10.1084/jem.20040874 CrossRefPubMedPubMedCentralGoogle Scholar
  20. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, McElrath MJ, Casimiro DR, Gottesdiener KM, Chodakewitz JA, Corey L, Robertson MN, Step Study Protocol T (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the step study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372(9653):1881–1893.  https://doi.org/10.1016/S0140-6736(08)61591-3 CrossRefPubMedPubMedCentralGoogle Scholar
  21. Caillat-Zucman S, Gimenez JJ, Wambergue F, Albouze G, Lebkiri B, Naret C, Moynot A, Jungers P, Bach JF (1998) Distinct HLA class II alleles determine antibody response to vaccination with hepatitis B surface antigen. Kidney Int 53(6):1626–1630.  https://doi.org/10.1046/j.1523-1755.1998.00909.x CrossRefPubMedGoogle Scholar
  22. Carnathan DG, Wetzel KS, Yu J, Lee ST, Johnson BA, Paiardini M, Yan J, Morrow MP, Sardesai NY, Weiner DB, Ertl HC, Silvestri G (2015) Activated CD4+CCR5+ T cells in the rectum predict increased SIV acquisition in SIVGag/Tat-vaccinated rhesus macaques. Proc Natl Acad Sci U S A 112(2):518–523.  https://doi.org/10.1073/pnas.1407466112 CrossRefPubMedGoogle Scholar
  23. Chuenarom W, Pitisuttihum P, Nitayaphan S, Chariyalertsak S, Kaewkungwal J, Kaewboon B, Phogat S, Karasavvas N, Sinangil F, Excler JL, Robb ML, Michael N, Kim JH, De Souza M, O’Connell R, Vasan S, Schuetz A, Group RS (2016) Late Boost Strategies of ALVAC-HIV/AIDSVAX B/E® prime-boost regimen (RV306) increased functional B cell responses and frequency of plasmablasts. Paper presented at the HIV research for preventionGoogle Scholar
  24. Chung AW, Ghebremichael M, Robinson H, Brown E, Choi I, Lane S, Dugast AS, Schoen MK, Rolland M, Suscovich TJ, Mahan AE, Liao L, Streeck H, Andrews C, Rerks-Ngarm S, Nitayaphan S, de Souza MS, Kaewkungwal J, Pitisuttithum P, Francis D, Michael NL, Kim JH, Bailey-Kellogg C, Ackerman ME, Alter G (2014) Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. Sci Transl Med 6(228):228ra238.  https://doi.org/10.1126/scitranslmed.3007736 CrossRefGoogle Scholar
  25. Chung AW, Kumar MP, Arnold KB, Yu WH, Schoen MK, Dunphy LJ, Suscovich TJ, Frahm N, Linde C, Mahan AE, Hoffner M, Streeck H, Ackerman ME, McElrath MJ, Schuitemaker H, Pau MG, Baden LR, Kim JH, Michael NL, Barouch DH, Lauffenburger DA, Alter G (2015) Dissecting polyclonal vaccine-induced humoral immunity against HIV using systems serology. Cell 163(4):988–998.  https://doi.org/10.1016/j.cell.2015.10.027 CrossRefPubMedPubMedCentralGoogle Scholar
  26. Churchyard G, Mlisana K, Karuna S, Williamson AL, Williamson C, Morris L, Tomaras GD, De Rosa SC, Gilbert PB, Gu N, Yu C, Mkhize NN, Hermanus T, Allen M, Pensiero M, Barnett SW, Gray G, Bekker LG, Montefiori DC, Kublin J, Corey L (2016) Sequential immunization with gp140 boosts immune responses primed by modified Vaccinia Ankara or DNA in HIV-uninfected south African participants. PLoS One 11(9):e0161753.  https://doi.org/10.1371/journal.pone.0161753 CrossRefPubMedPubMedCentralGoogle Scholar
  27. Corey L, Gilbert PB, Tomaras GD, Haynes BF, Pantaleo G, Fauci AS (2015) Immune correlates of vaccine protection against HIV-1 acquisition. Sci Transl Med 7(310):310rv317.  https://doi.org/10.1126/scitranslmed.aac7732 CrossRefGoogle Scholar
  28. de Bruyn G, Hudgens MG, Sullivan PS, Duerr AC (2005) Participant retention in clinical trials of candidate HIV vaccines. J Acquir Immune Defic Syndr 39(4):499–501CrossRefGoogle Scholar
  29. Deeks SG, Schweighardt B, Wrin T, Galovich J, Hoh R, Sinclair E, Hunt P, McCune JM, Martin JN, Petropoulos CJ, Hecht FM (2006) Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses. J Virol 80 (12):6155–6164. 80/12/6155 [pii]  https://doi.org/10.1128/JVI.00093-06 CrossRefGoogle Scholar
  30. Dhillon AK, Donners H, Pantophlet R, Johnson WE, Decker JM, Shaw GM, Lee FH, Richman DD, Doms RW, Vanham G, Burton DR (2007) Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol 81 (12):6548–6562. doi:JVI.02749–06 [pii]  https://doi.org/10.1128/JVI.02749-06
  31. Doores KJ, Burton DR (2010) Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J Virol 84(20):10510–10521.  https://doi.org/10.1128/JVI.00552-10 CrossRefPubMedPubMedCentralGoogle Scholar
  32. Durando P, Fenoglio D, Boschini A, Ansaldi F, Icardi G, Sticchi L, Renzoni A, Fabbri P, Ferrera A, Parodi A, Bruzzone B, Gabutti G, Podda A, Del Giudice G, Fragapane E, Indiveri F, Crovari P, Gasparini R (2008) Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and -seronegative adults. Clin Vaccine Immunol 15(2):253–259.  https://doi.org/10.1128/CVI.00316-07 CrossRefPubMedGoogle Scholar
  33. Easterhoff D, Moody MA, Fera D, Cheng H, Ackerman M, Wiehe K, Saunders KO, Pollara J, Vandergrift N, Parks R, Kim J, Michael NL, O’Connell RJ, Excler JL, Robb ML, Vasan S, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Nitayaphan S, Sinangil F, Tartaglia J, Phogat S, Kepler TB, Alam SM, Liao HX, Ferrari G, Seaman MS, Montefiori DC, Tomaras GD, Harrison SC, Haynes BF (2017) Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial. PLoS Pathog 13(2):e1006182.  https://doi.org/10.1371/journal.ppat.1006182 CrossRefPubMedPubMedCentralGoogle Scholar
  34. Edlefsen PT, Gilbert PB, Rolland M (2013) Sieve analysis in HIV-1 vaccine efficacy trials. Curr Opin HIV AIDS 8(5):432–436.  https://doi.org/10.1097/COH.0b013e328362db2b CrossRefPubMedGoogle Scholar
  35. Edlefsen PT, Rolland M, Hertz T, Tovanabutra S, Gartland AJ, deCamp AC, Magaret CA, Ahmed H, Gottardo R, Juraska M, McCoy C, Larsen BB, Sanders-Buell E, Carrico C, Menis S, Kijak GH, Bose M, Team RVS, Arroyo MA, O’Connell RJ, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Rerks-Ngarm S, Robb ML, Kirys T, Georgiev IS, Kwong PD, Scheffler K, Pond SL, Carlson JM, Michael NL, Schief WR, Mullins JI, Kim JH, Gilbert PB (2015) Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trial. PLoS Comput Biol 11(2):e1003973.  https://doi.org/10.1371/journal.pcbi.1003973 CrossRefPubMedPubMedCentralGoogle Scholar
  36. Eller M, Pegu P, Schuetz A, Kim D, Pitisuttihum P, Nitayaphan S, Chariyalertsak S, Phogat S, Sinangil F, Excler JL, Kim JH, Robb ML, Michael N, O’Connell R, Vasan S, Group RS (2017) Interval of ALVAC-HIV/AIDSVAX® B/E vaccine late boosting (RV306) alters CD4+ T-cell polyfunctionality and functional distribution. Paper presented at the keystone HIV vaccine conferenceGoogle Scholar
  37. Enterprise VWGoGHV, Voronin Y, Zinszner H, Karg C, Brooks K, Coombs R, Hural J, Holt R, Fast P, Allen M (2015) HIV vaccine-induced sero-reactivity: a challenge for trial participants, researchers, and physicians. Vaccine 33(10):1243–1249.  https://doi.org/10.1016/j.vaccine.2014.10.040 CrossRefGoogle Scholar
  38. Etcheverry MF, Evans JL, Sanchez E, Mendez-Arancibia E, Merono M, Gatell JM, Page K, Joseph J (2013) Enhanced retention strategies and willingness to participate among hard-to-reach female sex workers in Barcelona for HIV prevention and vaccine trials. Hum Vaccin Immunother 9(2):420–429CrossRefGoogle Scholar
  39. Fera D, Schmidt AG, Haynes BF, Gao F, Liao HX, Kepler TB, Harrison SC (2014) Affinity maturation in an HIV broadly neutralizing B-cell lineage through reorientation of variable domains. Proc Natl Acad Sci U S A 111(28):10275–10280.  https://doi.org/10.1073/pnas.1409954111 CrossRefPubMedPubMedCentralGoogle Scholar
  40. Ferrari G, Pollara J, Kozink D, Harms T, Drinker M, Freel S, Moody MA, Alam SM, Tomaras GD, Ochsenbauer C, Kappes JC, Shaw GM, Hoxie JA, Robinson JE, Haynes BF (2011) An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum. J Virol 85(14):7029–7036.  https://doi.org/10.1128/JVI.00171-11 CrossRefPubMedPubMedCentralGoogle Scholar
  41. Fitzgerald DW, Janes H, Robertson M, Coombs R, Frank I, Gilbert P, Loufty M, Mehrotra D, Duerr A, Step Study Protocol T (2011) An Ad5-vectored HIV-1 vaccine elicits cell-mediated immunity but does not affect disease progression in HIV-1-infected male subjects: results from a randomized placebo-controlled trial (the Step study). J Infect Dis 203(6):765–772.  https://doi.org/10.1093/infdis/jiq114 CrossRefPubMedPubMedCentralGoogle Scholar
  42. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF, rgp HIVVSG (2005) Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 191(5):654–665.  https://doi.org/10.1086/428404 CrossRefPubMedGoogle Scholar
  43. Gao F, Korber BT, Weaver E, Liao HX, Hahn BH, Haynes BF (2004) Centralized immunogens as a vaccine strategy to overcome HIV-1 diversity. Expert Rev Vaccines 3 (4 Suppl):S161–S168. doi:ERV0304S14 [pii]Google Scholar
  44. Gaschen B, Taylor J, Yusim K, Foley B, Gao F, Lang D, Novitsky V, Haynes B, Hahn BH, Bhattacharya T, Korber B (2002) Diversity considerations in HIV-1 vaccine selection. Science 296 (5577):2354–2360. doi: https://doi.org/10.1126/science.1070441 296/5577/2354 [pii]
  45. Gilbert PB, Peterson ML, Follmann D, Hudgens MG, Francis DP, Gurwith M, Heyward WL, Jobes DV, Popovic V, Self SG, Sinangil F, Burke D, Berman PW (2005) Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 191(5):666–677.  https://doi.org/10.1086/428405 CrossRefPubMedGoogle Scholar
  46. Gottardo R, Bailer RT, Korber BT, Gnanakaran S, Phillips J, Shen X, Tomaras GD, Turk E, Imholte G, Eckler L, Wenschuh H, Zerweck J, Greene K, Gao H, Berman PW, Francis D, Sinangil F, Lee C, Nitayaphan S, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Tartaglia J, Robb ML, Michael NL, Kim JH, Zolla-Pazner S, Haynes BF, Mascola JR, Self S, Gilbert P, Montefiori DC (2013) Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. PLoS One 8(9):e75665.  https://doi.org/10.1371/journal.pone.0075665 CrossRefPubMedPubMedCentralGoogle Scholar
  47. Gray ES, Taylor N, Wycuff D, Moore PL, Tomaras GD, Wibmer CK, Puren A, DeCamp A, Gilbert PB, Wood B, Montefiori DC, Binley JM, Shaw GM, Haynes BF, Mascola JR, Morris L (2009) Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. J Virol 83 (17):8925–8937. doi:JVI.00758-09 [pii]  https://doi.org/10.1128/JVI.00758-09
  48. Gray GE, Allen M, Moodie Z, Churchyard G, Bekker LG, Nchabeleng M, Mlisana K, Metch B, de Bruyn G, Latka MH, Roux S, Mathebula M, Naicker N, Ducar C, Carter DK, Puren A, Eaton N, McElrath MJ, Robertson M, Corey L, Kublin JG, HPs t (2011) Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis 11(7):507–515.  https://doi.org/10.1016/S1473-3099(11)70098-6 CrossRefPubMedPubMedCentralGoogle Scholar
  49. Gray G, Andersen-Nissen E, Grunenberg N, Huang Y, Roux S, Laher F, Innes C, Gu N, DiazGranados C, Phogat S, Lee C, Swann E, Kim JH, O’Connell R, Michael N, Flach B, DeRosa S, McElrath MJ, Corey L, 097 H (2014) HVTN 097: evaluation of the RV144 vaccine regimen in HIV uninfected south African adults. AIDS Res Hum Retrovir 30(S1)CrossRefGoogle Scholar
  50. Griffiss JM (1975) Bactericidal activity of meningococcal antisera. Blocking by IgA of lytic antibody in human convalescent sera. J Immunol 114(6):1779–1784PubMedGoogle Scholar
  51. Haase AT (2010) Targeting early infection to prevent HIV-1 mucosal transmission. Nature 464 (7286):217–223. doi:nature08757 [pii]  https://doi.org/10.1038/nature08757
  52. Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, Koblin BA, Buchbinder SP, Keefer MC, Tomaras GD, Frahm N, Hural J, Anude C, Graham BS, Enama ME, Adams E, DeJesus E, Novak RM, Frank I, Bentley C, Ramirez S, Fu R, Koup RA, Mascola JR, Nabel GJ, Montefiori DC, Kublin J, McElrath MJ, Corey L, Gilbert PB, Team HS (2013) Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med 369(22):2083–2092.  https://doi.org/10.1056/NEJMoa1310566 CrossRefPubMedPubMedCentralGoogle Scholar
  53. Harrison K, Vlahov D, Jones K, Charron K, Clements ML (1995) Medical eligibility, comprehension of the consent process, and retention of injection drug users recruited for an HIV vaccine trial. J Acquir Immune Defic Syndr 10(3):386–390Google Scholar
  54. Harro CD, Judson FN, Gorse GJ, Mayer KH, Kostman JR, Brown SJ, Koblin B, Marmor M, Bartholow BN, Popovic V, Group VAXS (2004) Recruitment and baseline epidemiologic profile of participants in the first phase 3 HIV vaccine efficacy trial. J Acquir Immune Defic Syndr 37(3):1385–1392CrossRefGoogle Scholar
  55. Haynes BF, Fleming J, St Clair EW, Katinger H, Stiegler G, Kunert R, Robinson J, Scearce RM, Plonk K, Staats HF, Ortel TL, Liao HX, Alam SM (2005) Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308 (5730):1906–1908. doi:1111781 [pii]  https://doi.org/10.1126/science.1111781
  56. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, Liao HX, DeVico AL, Lewis GK, Williams C, Pinter A, Fong Y, Janes H, DeCamp A, Huang Y, Rao M, Billings E, Karasavvas N, Robb ML, Ngauy V, de Souza MS, Paris R, Ferrari G, Bailer RT, Soderberg KA, Andrews C, Berman PW, Frahm N, De Rosa SC, Alpert MD, Yates NL, Shen X, Koup RA, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Rerks-Ngarm S, Michael NL, Kim JH (2012) Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 366(14):1275–1286.  https://doi.org/10.1056/NEJMoa1113425 CrossRefPubMedPubMedCentralGoogle Scholar
  57. Hemelaar J (2012) The origin and diversity of the HIV-1 pandemic. Trends Mol Med 18(3):182–192.  https://doi.org/10.1016/j.molmed.2011.12.001 CrossRefPubMedGoogle Scholar
  58. Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, Bakker JM, Lanigan CM, Landucci G, Forthal DN, Parren PW, Marx PA, Burton DR (2007) Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449(7158):101–104.  https://doi.org/10.1038/nature06106 CrossRefGoogle Scholar
  59. Hu H, Eller MA, Zafar S, Zhou Y, Gu M, Wei Z, Currier JR, Marovich MA, Kibuuka HN, Bailer RT, Koup RA, Robb ML, Michael NL, Kim JH, Ratto-Kim S (2014) Preferential infection of human Ad5-specific CD4 T cells by HIV in Ad5 naturally exposed and recombinant Ad5-HIV vaccinated individuals. Proc Natl Acad Sci U S A 111(37):13439–13444.  https://doi.org/10.1073/pnas.1400446111 CrossRefPubMedPubMedCentralGoogle Scholar
  60. Hutnick NA, Carnathan DG, Dubey SA, Makedonas G, Cox KS, Kierstead L, Ratcliffe SJ, Robertson MN, Casimiro DR, Ertl HC, Betts MR (2009) Baseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4+ T cells. Nat Med 15(8):876–878.  https://doi.org/10.1038/nm.1989 CrossRefPubMedPubMedCentralGoogle Scholar
  61. Janes H, Gilbert P, Buchbinder S, Kublin J, Sobieszczyk ME, Hammer SM (2013) In pursuit of an HIV vaccine: designing efficacy trials in the context of partially effective nonvaccine prevention modalities. AIDS Res Hum Retrovir 29(11):1513–1523.  https://doi.org/10.1089/AID.2012.0385 CrossRefPubMedGoogle Scholar
  62. Jiang X, Burke V, Totrov M, Williams C, Cardozo T, Gorny MK, Zolla-Pazner S, Kong XP (2010) Conserved structural elements in the V3 crown of HIV-1 gp120. Nat Struct Mol Biol 17 (8):955–961. doi:nsmb.1861 [pii]  https://doi.org/10.1038/nsmb.1861
  63. Karasavvas N, Billings E, Rao M, Williams C, Zolla-Pazner S, Bailer RT, Koup RA, Madnote S, Arworn D, Shen X, Tomaras GD, Currier JR, Jiang M, Magaret C, Andrews C, Gottardo R, Gilbert P, Cardozo TJ, Rerks-Ngarm S, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Paris R, Greene K, Gao H, Gurunathan S, Tartaglia J, Sinangil F, Korber BT, Montefiori DC, Mascola JR, Robb ML, Haynes BF, Ngauy V, Michael NL, Kim JH, de Souza MS, Collaboration MT (2012) The Thai phase III HIV type 1 vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retrovir 28 (11):1444–1457. doi: https://doi.org/10.1089/aid.2012.0103
  64. Kepler TB, Liao HX, Alam SM, Bhaskarabhatla R, Zhang R, Yandava C, Stewart S, Anasti K, Kelsoe G, Parks R, Lloyd KE, Stolarchuk C, Pritchett J, Solomon E, Friberg E, Morris L, Karim SS, Cohen MS, Walter E, Moody MA, Wu X, Altae-Tran HR, Georgiev IS, Kwong PD, Boyd SD, Fire AZ, Mascola JR, Haynes BF (2014) Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodies. Cell Host Microbe 16(3):304–313.  https://doi.org/10.1016/j.chom.2014.08.006 CrossRefPubMedPubMedCentralGoogle Scholar
  65. Kim JH, Excler JL, Michael NL (2015) Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection. Annu Rev Med 66:423–437.  https://doi.org/10.1146/annurev-med-052912-123749 CrossRefPubMedGoogle Scholar
  66. Klein J, Sato A (2000) The HLA system. First of two parts. N Engl J Med 343(10):702–709.  https://doi.org/10.1056/NEJM200009073431006 CrossRefPubMedGoogle Scholar
  67. Larsen M, Sauce D, Arnaud L, Fastenackels S, Appay V, Gorochov G (2012) Evaluating cellular polyfunctionality with a novel polyfunctionality index. PLoS One 7(7):e42403.  https://doi.org/10.1371/journal.pone.0042403 CrossRefPubMedPubMedCentralGoogle Scholar
  68. Lazarus EM, Otwombe K, Adonis T, Sebastian E, Gray G, Grunenberg N, Roux S, Churchyard G, Innes C, Laher F (2014) Uptake of genital mucosal sampling in HVTN 097, a phase 1b HIV vaccine trial in South Africa. PLoS One 9(11):e112303.  https://doi.org/10.1371/journal.pone.0112303 CrossRefPubMedPubMedCentralGoogle Scholar
  69. Liao HX, Sutherland LL, Xia SM, Brock ME, Scearce RM, Vanleeuwen S, Alam SM, McAdams M, Weaver EA, Camacho Z, Ma BJ, Li Y, Decker JM, Nabel GJ, Montefiori DC, Hahn BH, Korber BT, Gao F, Haynes BF (2006) A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology 353(2):268–282CrossRefGoogle Scholar
  70. Liao HX, Chen X, Munshaw S, Zhang R, Marshall DJ, Vandergrift N, Whitesides JF, Lu X, Yu JS, Hwang KK, Gao F, Markowitz M, Heath SL, Bar KJ, Goepfert PA, Montefiori DC, Shaw GC, Alam SM, Margolis DM, Denny TN, Boyd SD, Marshal E, Egholm M, Simen BB, Hanczaruk B, Fire AZ, Voss G, Kelsoe G, Tomaras GD, Moody MA, Kepler TB, Haynes BF (2011) Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. J Exp Med 208(11):2237–2249. jem.20110363 [pii]  https://doi.org/10.1084/jem.20110363 CrossRefGoogle Scholar
  71. Liao HX, Bonsignori M, Alam SM, McLellan JS, Tomaras GD, Moody MA, Kozink DM, Hwang KK, Chen X, Tsao CY, Liu P, Lu X, Parks RJ, Montefiori DC, Ferrari G, Pollara J, Rao M, Peachman KK, Santra S, Letvin NL, Karasavvas N, Yang ZY, Dai K, Pancera M, Gorman J, Wiehe K, Nicely NI, Rerks-Ngarm S, Nitayaphan S, Kaewkungwal J, Pitisuttithum P, Tartaglia J, Sinangil F, Kim JH, Michael NL, Kepler TB, Kwong PD, Mascola JR, Nabel GJ, Pinter A, Zolla-Pazner S, Haynes BF (2013) Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 38(1):176–186.  https://doi.org/10.1016/j.immuni.2012.11.011 CrossRefPubMedPubMedCentralGoogle Scholar
  72. Lin L, Finak G, Ushey K, Seshadri C, Hawn TR, Frahm N, Scriba TJ, Mahomed H, Hanekom W, Bart PA, Pantaleo G, Tomaras GD, Rerks-Ngarm S, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Michael NL, Kim JH, Robb ML, O’Connell RJ, Karasavvas N, Gilbert P, CDR S, McElrath MJ, Gottardo R (2015) COMPASS identifies T-cell subsets correlated with clinical outcomes. Nat Biotechnol 33(6):610–616.  https://doi.org/10.1038/nbt.3187 CrossRefPubMedPubMedCentralGoogle Scholar
  73. Liu J, Ghneim K, Sok D, Bosche WJ, Li Y, Chipriano E, Berkemeier B, Oswald K, Borducchi E, Cabral C, Peter L, Brinkman A, Shetty M, Jimenez J, Mondesir J, Lee B, Giglio P, Chandrashekar A, Abbink P, Colantonio A, Gittens C, Baker C, Wagner W, Lewis MG, Li W, Sekaly RP, Lifson JD, Burton DR, Barouch DH (2016) Antibody-mediated protection against SHIV challenge includes systemic clearance of distal virus. Science 353(6303):1045–1049.  https://doi.org/10.1126/science.aag0491 CrossRefPubMedPubMedCentralGoogle Scholar
  74. Mathew GD, Qualtiere LF, Neel HB, 3rd, Pearson GR (1981) IgA antibody, antibody-dependent cellular cytotoxicity and prognosis in patients with nasopharyngeal carcinoma. Int J Cancer 27 (2):175–180CrossRefGoogle Scholar
  75. Matyas GR, Beck Z, Karasavvas N, Alving CR (2009) Lipid binding properties of 4E10, 2F5, and WR304 monoclonal antibodies that neutralize HIV-1. Biochim Biophys Acta 1788 (3):660–665. doi:S0005–2736(08)00378–7 [pii]  https://doi.org/10.1016/j.bbamem.2008.11.015
  76. Meffre E, Milili M, Blanco-Betancourt C, Antunes H, Nussenzweig MC, Schiff C (2001) Immunoglobulin heavy chain expression shapes the B cell receptor repertoire in human B cell development. J Clin Invest 108(6):879–886.  https://doi.org/10.1172/JCI13051 CrossRefPubMedPubMedCentralGoogle Scholar
  77. Miller CJ, Li Q, Abel K, Kim EY, Ma ZM, Wietgrefe S, La Franco-Scheuch L, Compton L, Duan L, Shore MD, Zupancic M, Busch M, Carlis J, Wolinsky S, Haase AT (2005) Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J Virol 79(14):9217–9227. doi:79/14/9217 [pii]  https://doi.org/10.1128/JVI.79.14.9217-9227.2005
  78. Montefiori DC, Karnasuta C, Huang Y, Ahmed H, Gilbert P, de Souza MS, McLinden R, Tovanabutra S, Laurence-Chenine A, Sanders-Buell E, Moody MA, Bonsignori M, Ochsenbauer C, Kappes J, Tang H, Greene K, Gao H, LaBranche CC, Andrews C, Polonis VR, Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Self SG, Berman PW, Francis D, Sinangil F, Lee C, Tartaglia J, Robb ML, Haynes BF, Michael NL, Kim JH (2012) Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis 206(3):431–441.  https://doi.org/10.1093/infdis/jis367 CrossRefPubMedPubMedCentralGoogle Scholar
  79. Moody MA, Yates NL, Amos JD, Drinker MS, Eudailey JA, Gurley TC, Marshall DJ, Whitesides JF, Chen X, Foulger A, Yu JS, Zhang R, Meyerhoff RR, Parks R, Scull JC, Wang L, Vandergrift NA, Pickeral J, Pollara J, Kelsoe G, Alam SM, Ferrari G, Montefiori DC, Voss G, Liao HX, Tomaras GD, Haynes BF (2012) HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages. J Virol 86(14):7496–7507.  https://doi.org/10.1128/JVI.00426-12 CrossRefPubMedPubMedCentralGoogle Scholar
  80. Mouquet H, Scheid JF, Zoller MJ, Krogsgaard M, Ott RG, Shukair S, Artyomov MN, Pietzsch J, Connors M, Pereyra F, Walker BD, Ho DD, Wilson PC, Seaman MS, Eisen HN, Chakraborty AK, Hope TJ, Ravetch JV, Wardemann H, Nussenzweig MC (2010) Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature 467 (7315):591–595. doi:nature09385 [pii]  https://doi.org/10.1038/nature09385
  81. Mouquet H, Warncke M, Scheid JF, Seaman MS, Nussenzweig MC (2012) Enhanced HIV-1 neutralization by antibody heteroligation. Proc Natl Acad Sci U S A 109(3):875–880. doi:1120059109 [pii]  https://doi.org/10.1073/pnas.1120059109
  82. Ndhlovu ZM, Piechocka-Trocha A, Vine S, McMullen A, Koofhethile KC, Goulder PJ, Ndung’u T, Barouch DH, Walker BD (2011) Mosaic HIV-1 Gag antigens can be processed and presented to human HIV-specific CD8+ T cells. J Immunol 186 (12):6914–6924. doi:jimmunol.1004231 [pii]  https://doi.org/10.4049/jimmunol.1004231
  83. Newman PA, Lee SJ, Duan N, Rudy E, Nakazono TK, Boscardin J, Kakinami L, Shoptaw S, Diamant A, Cunningham WE (2009) Preventive HIV vaccine acceptability and behavioral risk compensation among a random sample of high-risk adults in Los Angeles (LA VOICES). Health Serv Res 44(6):2167–2179.  https://doi.org/10.1111/j.1475-6773.2009.01039.x CrossRefPubMedPubMedCentralGoogle Scholar
  84. Newman PA, Roungprakhon S, Tepjan S, Yim S (2010) Preventive HIV vaccine acceptability and behavioral risk compensation among high-risk men who have sex with men and transgenders in Thailand. Vaccine 28(4):958–964.  https://doi.org/10.1016/j.vaccine.2009.10.142 CrossRefPubMedGoogle Scholar
  85. Newton MA, Noueiry A, Sarkar D, Ahlquist P (2004) Detecting differential gene expression with a semiparametric hierarchical mixture method. Biostatistics 5(2):155–176.  https://doi.org/10.1093/biostatistics/5.2.155 CrossRefPubMedGoogle Scholar
  86. Nitayaphan S, Khamboonruang C, Sirisophana N, Morgan P, Chiu J, Duliege AM, Chuenchitra C, Supapongse T, Rungruengthanakit K, deSouza M, Mascola JR, Boggio K, Ratto-Kim S, Markowitz LE, Birx D, Suriyanon V, McNeil JG, Brown AE, Michael RA (2000) A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative thais.AFRIMS-RIHES vaccine evaluation group. Armed forces research Institute of Medical Sciences and the research institute for health sciences. Vaccine 18(15):1448–1455CrossRefGoogle Scholar
  87. Nitayaphan S, Pitisuttithum P, Karnasuta C, Eamsila C, de Souza M, Morgan P, Polonis V, Benenson M, VanCott T, Ratto-Kim S, Kim J, Thapinta D, Garner R, Bussaratid V, Singharaj P, el-Habib R, Gurunathan S, Heyward W, Birx D, McNeil J, Brown AE, Thai AVEG (2004) Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. J Infect Dis 190(4):702–706.  https://doi.org/10.1086/422258 CrossRefPubMedGoogle Scholar
  88. Nkolola JP, Bricault CA, Cheung A, Shields J, Perry J, Kovacs JM, Giorgi E, van Winsen M, Apetri A, Brinkman-van der Linden EC, Chen B, Korber B, Seaman MS, Barouch DH (2014) Characterization and immunogenicity of a novel mosaic M HIV-1 gp140 trimer. J Virol 88 (17):9538–9552. doi: https://doi.org/10.1128/JVI.01739-14 CrossRefGoogle Scholar
  89. O’Brien KL, Liu J, King SL, Sun YH, Schmitz JE, Lifton MA, Hutnick NA, Betts MR, Dubey SA, Goudsmit J, Shiver JW, Robertson MN, Casimiro DR, Barouch DH (2009) Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans. Nat Med 15(8):873–875.  https://doi.org/10.1038/nm.1991 CrossRefPubMedPubMedCentralGoogle Scholar
  90. Ovsyannikova IG, Jacobson RM, Vierkant RA, Pankratz VS, Poland GA (2007) HLA supertypes and immune responses to measles-mumps-rubella viral vaccine: findings and implications for vaccine design. Vaccine 25(16):3090–3100.  https://doi.org/10.1016/j.vaccine.2007.01.020 CrossRefPubMedGoogle Scholar
  91. Panico M, Bouche L, Binet D, O’Connor MJ, Rahman D, Pang PC, Canis K, North SJ, Desrosiers RC, Chertova E, Keele BF, Bess JW, Jr., Lifson JD, Haslam SM, Dell A, Morris HR (2016) Mapping the complete glycoproteome of virion-derived HIV-1 gp120 provides insights into broadly neutralizing antibody binding. Sci Reports 6:32956. doi: https://doi.org/10.1038/srep32956
  92. Paris R, Bejrachandra S, Thongcharoen P, Nitayaphan S, Pitisuttithum P, Sambor A, Gurunathan S, Francis D, Ratto-Kim S, Karnasuta C, de Souza MS, Polonis VR, Brown AE, Kim JH, Stephens HA, Thai AVEG (2012) HLA class II restriction of HIV-1 clade-specific neutralizing antibody responses in ethnic Thai recipients of the RV144 prime-boost vaccine combination of ALVAC-HIV and AIDSVAX((R)) B/E. Vaccine 30(5):832–836.  https://doi.org/10.1016/j.vaccine.2011.11.002 CrossRefPubMedGoogle Scholar
  93. Pitisuttihum P, Nitayaphan S, chariyalertsak S, karasavvas N, Kaewkungwal J, Ngauy V, Vasan S, Robb ML, Michael N, Brown K, Andrews C, Phonrat B, Dhitavat J, Excler JL, Kim JH, O’Connell R (2014) RV306, an evaluation of a 48 Week ALVAC-HIV AIDSVAX B/E vaccination regimen in Thailand: Participation rates for optional specimen collections. Paper presented at the HIV research for preventionGoogle Scholar
  94. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, Hu D, Tappero JW, Choopanya K, Bangkok Vaccine Evaluation G (2006) Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 194(12):1661–1671.  https://doi.org/10.1086/508748 CrossRefPubMedGoogle Scholar
  95. Plotkin SA (2010) Correlates of protection induced by vaccination. Clin Vaccine Immunol 17(7):1055–1065.  https://doi.org/10.1128/CVI.00131-10 CrossRefPubMedPubMedCentralGoogle Scholar
  96. Plotkin SA, Gilbert PB (2012) Nomenclature for immune correlates of protection after vaccination. Clin Infect Dis 54(11):1615–1617.  https://doi.org/10.1093/cid/cis238 CrossRefPubMedPubMedCentralGoogle Scholar
  97. Pollara J, Bonsignori M, Moody MA, Liu P, Alam SM, Hwang KK, Gurley TC, Kozink DM, Armand LC, Marshall DJ, Whitesides JF, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Robb ML, O’Connell RJ, Kim JH, Michael NL, Montefiori DC, Tomaras GD, Liao HX, Haynes BF, Ferrari G (2014) HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities. J Virol 88(14):7715–7726.  https://doi.org/10.1128/JVI.00156-14 CrossRefPubMedPubMedCentralGoogle Scholar
  98. Pollara J, Easterhoff D, Luo K, Moody MA, Huffman T, Wiehe K, Saunders KO, Parks R, Kim JH, Michael N, O’Connell R, Excler JL, Robb ML, Vasan S, Rerks-Ngarm S, Kaewkungwal J, Pitisuttihum P, Nitayaphan S, Sinangil F, Tartaglia J, Phogat S, Kepler TB, Alam SM, Montefiori DC, Ferrari G, Haynes BF (2017) Induction of new broadly potent ADCC responses in RV144 vaccinees with boosts 6–8 years after initial vaccination. Paper presented at the keystone HIV vaccine conferenceGoogle Scholar
  99. Prentice HA, Tomaras GD, Geraghty DE, Apps R, Fong Y, Ehrenberg PK, Rolland M, Kijak GH, Krebs SJ, Nelson W, DeCamp A, Shen X, Yates NL, Zolla-Pazner S, Nitayaphan S, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Ferrari G, McElrath MJ, Montefiori DC, Bailer RT, Koup RA, O’Connell RJ, Robb ML, Michael NL, Gilbert PB, Kim JH, Thomas R (2015) HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition. Sci Transl Med 7(296):296ra112.  https://doi.org/10.1126/scitranslmed.aab4005 CrossRefPubMedPubMedCentralGoogle Scholar
  100. Pulendran B, Ahmed R (2011) Immunological mechanisms of vaccination. Nat Immunol 12(6):509–517CrossRefGoogle Scholar
  101. Qin L, Gilbert PB, Corey L, McElrath MJ, Self SG (2007) A framework for assessing immunological correlates of protection in vaccine trials. J Infect Dis 196(9):1304–1312.  https://doi.org/10.1086/522428 CrossRefPubMedGoogle Scholar
  102. Ratto-Kim S, de Souza MS, Currier JR, Karasavvas N, Sidney J, Rolland M, Valencia-Micolta A, Madnote S, Sette A, Nitayaphan S, Pitisuttuthum P, Kaewkungwal J, Rerks-Ngarm S, O’Connell R, Michael N, Robb ML, Marovich M, Kim JH (2015) Identification of immunodominant CD4-restricted epitopes co-located with antibody binding sites in individuals vaccinated with ALVAC-HIV and AIDSVAX B/E. PLoS One 10(2):e0115582.  https://doi.org/10.1371/journal.pone.0115582 CrossRefPubMedPubMedCentralGoogle Scholar
  103. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH, Investigators M-T (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361(23):2209–2220.  https://doi.org/10.1056/NEJMoa0908492 CrossRefPubMedGoogle Scholar
  104. Rerks-Ngarm S, Pitisuttihum P, Excler JL, Nitayaphan S, Kaewkungwal J, Premsri N, Kunasol P, Karasavvas N, Schuetz A, Nguay V, Sinangil F, Dawson P, DeCamp A, Gurunathan S, Tartaglia J, DiazGranados C, Ratto-Kim S, Pegu P, Eller M, Karnasuta C, Montefiori DC, Sawant S, Vangdergrift N, Wills S, Tomaras GD, Robb ML, Michael N, Kim JH, Vasan S, O’Connell R, Group RS (2017) Randomized, double blind evaluation of late boost strategies for HIV-uninfected vaccine recipients in the RV144 HIV vaccine efficacy trial. J Infect Dis 215(8):1255–1263CrossRefGoogle Scholar
  105. Robb ML, Rerks-Ngarm S, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Kunasol P, Khamboonruang C, Thongcharoen P, Morgan P, Benenson M, Paris RM, Chiu J, Adams E, Francis D, Gurunathan S, Tartaglia J, Gilbert P, Stablein D, Michael NL, Kim JH (2012) Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infect Dis 12(7):531–537.  https://doi.org/10.1016/S1473-3099(12)70088-9 CrossRefPubMedPubMedCentralGoogle Scholar
  106. Rolland M, Edlefsen PT, Larsen BB, Tovanabutra S, Sanders-Buell E, Hertz T, deCamp AC, Carrico C, Menis S, Magaret CA, Ahmed H, Juraska M, Chen L, Konopa P, Nariya S, Stoddard JN, Wong K, Zhao H, Deng W, Maust BS, Bose M, Howell S, Bates A, Lazzaro M, O’Sullivan A, Lei E, Bradfield A, Ibitamuno G, Assawadarachai V, O’Connell RJ, deSouza MS, Nitayaphan S, Rerks-Ngarm S, Robb ML, McLellan JS, Georgiev I, Kwong PD, Carlson JM, Michael NL, Schief WR, Gilbert PB, Mullins JI, Kim JH (2012) Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 490(7420):417–420.  https://doi.org/10.1038/nature11519 CrossRefPubMedPubMedCentralGoogle Scholar
  107. Santra S, Liao HX, Zhang R, Muldoon M, Watson S, Fischer W, Theiler J, Szinger J, Balachandran H, Buzby A, Quinn D, Parks RJ, Tsao CY, Carville A, Mansfield KG, Pavlakis GN, Felber BK, Haynes BF, Korber BT, Letvin NL (2010) Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat Med 16 (3):324–328. doi:nm.2108 [pii]  https://doi.org/10.1038/nm.2108
  108. Sather DN, Armann J, Ching LK, Mavrantoni A, Sellhorn G, Caldwell Z, Yu X, Wood B, Self S, Kalams S, Stamatatos L (2009) Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol 83 (2):757–769. doi:JVI.02036-08 [pii]  https://doi.org/10.1128/JVI.02036-08
  109. Schief WR, Ban YE, Stamatatos L (2009) Challenges for structure-based HIV vaccine design. Curr Opin HIV AIDS 4 (5):431–440. doi: https://doi.org/10.1097/COH.0b013e32832e6184 01222929-200909000-00014 [pii]
  110. Schuetz A, Phuangngern Y, Pitisuttihum P, Nitayaphan S, Chariyalertsak S, Phanuphak N, Kaewkungwal J, Excler JL, Ananworanich J, Robb ML, Phogat S, Michael N, Kim JH, O’Connell R, Vasan S, Groups RS (2016) ALVAC-HIV/AIDSVAX B/E vaccination does not induce activation of sigmoid CD4+CCR5+ T cells. Paper presented at the keystone HIV vaccine conferenceGoogle Scholar
  111. Schuetz A, Eller M, Puangngern Y, Pegu P, Pitisuttihum P, Nitayaphan S, Chariyalertsak S, Phanuphak N, Kaewkungwal J, Excler JL, Phogat S, Kim JH, Robb ML, Michael N, O’Connell R, Vasan S, Group RS (2017) Differential peripheral and mucosal cellular immune responses induced by ALVAC-HIV/AIDSVAX B/E late boost strategies (RV306). Paper presented at the keystone HIV vaccine conferenceGoogle Scholar
  112. Seaman MS, Janes H, Hawkins N, Grandpre LE, Devoy C, Giri A, Coffey RT, Harris L, Wood B, Daniels MG, Bhattacharya T, Lapedes A, Polonis VR, McCutchan FE, Gilbert PB, Self SG, Korber BT, Montefiori DC, Mascola JR (2010) Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol 84(3):1439–1452.  https://doi.org/10.1128/JVI.02108-09 CrossRefPubMedPubMedCentralGoogle Scholar
  113. Simek MD, Rida W, Priddy FH, Pung P, Carrow E, Laufer DS, Lehrman JK, Boaz M, Tarragona-Fiol T, Miiro G, Birungi J, Pozniak A, McPhee DA, Manigart O, Karita E, Inwoley A, Jaoko W, Dehovitz J, Bekker LG, Pitisuttithum P, Paris R, Walker LM, Poignard P, Wrin T, Fast PE, Burton DR, Koff WC (2009) Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J Virol 83 (14):7337–7348. doi:JVI.00110-09 [pii]  https://doi.org/10.1128/JVI.00110-09
  114. Sok D, Laserson U, Laserson J, Liu Y, Vigneault F, Julien JP, Briney B, Ramos A, Saye KF, Le K, Mahan A, Wang S, Kardar M, Yaari G, Walker LM, Simen BB, St John EP, Chan-Hui PY, Swiderek K, Kleinstein SH, Alter G, Seaman MS, Chakraborty AK, Koller D, Wilson IA, Church GM, Burton DR, Poignard P (2013) The effects of somatic hypermutation on neutralization and binding in the PGT121 family of broadly neutralizing HIV antibodies. PLoS Pathog 9(11):e1003754.  https://doi.org/10.1371/journal.ppat.1003754 CrossRefPubMedPubMedCentralGoogle Scholar
  115. Spira AI, Marx PA, Patterson BK, Mahoney J, Koup RA, Wolinsky SM, Ho DD (1996) Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J Exp Med 183(1):215–225CrossRefGoogle Scholar
  116. Stephens HA, Brown AE, Chandanayingyong D, Webster HK, Sirikong M, Longta P, Vangseratthana R, Gordon DM, Lekmak S, Rungruang E (1995) The presence of the HLA class II allele DPB1*0501 in ethnic Thais correlates with an enhanced vaccine-induced antibody response to a malaria sporozoite antigen. Eur J Immunol 25(11):3142–3147.  https://doi.org/10.1002/eji.1830251123 CrossRefPubMedGoogle Scholar
  117. Stewart-Jones GB, Soto C, Lemmin T, Chuang GY, Druz A, Kong R, Thomas PV, Wagh K, Zhou T, Behrens AJ, Bylund T, Choi CW, Davison JR, Georgiev IS, Joyce MG, Kwon YD, Pancera M, Taft J, Yang Y, Zhang B, Shivatare SS, Shivatare VS, Lee CC, Wu CY, Bewley CA, Burton DR, Koff WC, Connors M, Crispin M, Baxa U, Korber BT, Wong CH, Mascola JR, Kwong PD (2016) Trimeric HIV-1-Env structures define glycan shields from clades A, B, and G. Cell 165(4):813–826.  https://doi.org/10.1016/j.cell.2016.04.010 CrossRefPubMedPubMedCentralGoogle Scholar
  118. Thapinta D, Jenkins RA, Morgan PA, Chiu J, Boenim W, Bussaratid V, Chaddic C, Naksrisook S, Phonrat B, Sirijongdee N, Sornsathapornkul P, Sontirat A, Srisaengchai P, Suwanarach C, Wongkamhaeng S, Brown AE, Khamboonruang C, Nitayaphan S, Pitisuttithum P, Thongchareon P, Thai AVEG (2002) Recruiting volunteers for a multisite phase I/II HIV preventive vaccine trial in Thailand. J Acquir Immune Defic Syndr 30(5):503–513CrossRefGoogle Scholar
  119. Tomaras GD (2016) Overview of humoral and cellular immune responses to HIV vaccination. Paper presented at the HIV research for preventionGoogle Scholar
  120. Tomaras GD, Ferrari G, Shen X, Alam SM, Liao HX, Pollara J, Bonsignori M, Moody MA, Fong Y, Chen X, Poling B, Nicholson CO, Zhang R, Lu X, Parks R, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Gilbert PB, Kim JH, Michael NL, Montefiori DC, Haynes BF (2013) Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc Natl Acad Sci U S A 110(22):9019–9024.  https://doi.org/10.1073/pnas.1301456110 CrossRefPubMedPubMedCentralGoogle Scholar
  121. Vanichseni S, Tappero JW, Pitisuttithum P, Kitayaporn D, Mastro TD, Vimutisunthorn E, van Griensvan F, Heyward WL, Francis DP, Choopanya K, Bangkok Vaccine Evaluation G (2004) Recruitment, screening and characteristics of injection drug users participating in the AIDSVAX B/E HIV vaccine trial, Bangkok, Thailand. AIDS 18(2):311–316CrossRefGoogle Scholar
  122. Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC (2003) Predominant autoantibody production by early human B cell precursors. Science 301(5638):1374–1377.  https://doi.org/10.1126/science.1086907 CrossRefGoogle Scholar
  123. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, Komarova NL, Nowak MA, Hahn BH, Kwong PD, Shaw GM (2003) Antibody neutralization and escape by HIV-1. Nature 422(6929):307–312.  https://doi.org/10.1038/nature01470 CrossRefGoogle Scholar
  124. Wieczorek L, Pitisuttihum P, Nitayaphan S, Chariyalertsak S, Kaewkungwal J, Molnar S, Blaskowski S, Schoen J, Gao H, Greene K, Phogat S, Sinangil F, Michael N, Excler JL, Montefiori DC, Robb ML, Kim JH, Vasan S, O’Connell R, Polonis VR (2016) Delayed boost of ALVAC®HIV and AIDSVAX® B/E gp120 following the RV144 regimen, significantly increases HIV-1 neutralizing antibody responses. Paper presented at the HIV research for preventionGoogle Scholar
  125. Wieczorek L, Pitisuttihum P, Nitayaphan S, Chariyalertsak S, Kaewkungwal J, Molnar S, Schoen J, Gift S, Phogat S, Sinangil F, Michael N, Excler JL, Montefiori DC, Robb ML, Kim D, Vasan S, O’Connell R, Polonis VR (2017) Late boosting improves the durability of neutralizing antibody responses after vaccination with ALVAC®HIV and AIDSVAX® B/E gp120. Paper presented at the keystone HIV vaccine conferenceGoogle Scholar
  126. Williams LD, Yates NL, Lucas JT, Howington RV, Sawant S, Vandergrift NA, Kim JH, Michael N, Robb ML, O’Connell R, Vasan S, Excler JL, Rerks-Ngarm S, Pitisuttihum P, Nitayaphan S, Karasavvas N, Liao HX, Ferrari G, Montefiori DC, Haynes BF, Tomaras GD (2015) IgG3 subclass and specificity profiles elicited by the RV305 vaccine regimen. Paper presented at the keystone HIV vaccine conference,Google Scholar
  127. Yates NL, Liao HX, Fong Y, deCamp A, Vandergrift NA, Williams WT, Alam SM, Ferrari G, Yang ZY, Seaton KE, Berman PW, Alpert MD, Evans DT, O’Connell RJ, Francis D, Sinangil F, Lee C, Nitayaphan S, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Tartaglia J, Pinter A, Zolla-Pazner S, Gilbert PB, Nabel GJ, Michael NL, Kim JH, Montefiori DC, Haynes BF, Tomaras GD (2014) Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med 6(228):228ra239.  https://doi.org/10.1126/scitranslmed.3007730 CrossRefGoogle Scholar
  128. Young AM, Halgin DS, DiClemente RJ, Sterk CE, Havens JR (2014) Will HIV vaccination reshape HIV risk behavior networks? A social network analysis of drug users’ anticipated risk compensation. PLoS One 9(7):e101047.  https://doi.org/10.1371/journal.pone.0101047 CrossRefPubMedPubMedCentralGoogle Scholar
  129. Zolla-Pazner S, deCamp A, Gilbert PB, Williams C, Yates NL, Williams WT, Howington R, Fong Y, Morris DE, Soderberg KA, Irene C, Reichman C, Pinter A, Parks R, Pitisuttithum P, Kaewkungwal J, Rerks-Ngarm S, Nitayaphan S, Andrews C, O’Connell RJ, Yang ZY, Nabel GJ, Kim JH, Michael NL, Montefiori DC, Liao HX, Haynes BF, Tomaras GD (2014a) Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. PLoS One 9(2):e87572.  https://doi.org/10.1371/journal.pone.0087572 CrossRefPubMedPubMedCentralGoogle Scholar
  130. Zolla-Pazner S, Edlefsen PT, Rolland M, Kong XP, deCamp A, Gottardo R, Williams C, Tovanabutra S, Sharpe-Cohen S, Mullins JI, deSouza MS, Karasavvas N, Nitayaphan S, Rerks-Ngarm S, Pitisuttihum P, Kaewkungwal J, O’Connell RJ, Robb ML, Michael NL, Kim JH, Gilbert P (2014b) Vaccine-induced human antibodies specific for the third variable region of HIV-1 gp120 impose immune pressure on infecting viruses. EBioMedicine 1(1):37–45.  https://doi.org/10.1016/j.ebiom.2014.10.022 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  • Elizabeth Heger
    • 1
  • Alexandra Schuetz
    • 2
    • 3
    • 4
  • Sandhya Vasan
    • 2
    • 3
    • 4
    Email author
  1. 1.US Army Medical Materiel Development ActivityFort DetrickUSA
  2. 2.US Army Medical ComponentArmed Forces Research Institute of Medical SciencesBangkokThailand
  3. 3.US Military HIV Research Program, Walter Reed Army Institute of ResearchSilver SpringUSA
  4. 4.Henry M. Jackson FoundationBethesdaUSA

Personalised recommendations